Coronavirus disease

New Studies Conclude Xlear Kills and/or Deactivates SARS-CoV-2

Monday, November 30, 2020 - 8:00am

New in vitro studies, led by renowned authority on respiratory diseases, conclude Xlear nasal spray is an effective...and replicable means to deactivate SARS-CoV-2...to an undetectable amount of infectious virus.

Key Points: 
  • New in vitro studies, led by renowned authority on respiratory diseases, conclude Xlear nasal spray is an effective...and replicable means to deactivate SARS-CoV-2...to an undetectable amount of infectious virus.
  • The Virucidal Studies shed important light on the role Xlear can play in helping combat the COVID-19 pandemic, said Dr. Gustavo Ferrer, who is leading the research team.
  • Nasal sprays, such as Xlear, reduce viral load in the nose, which is vital in fighting COVID-19.
  • Building on the existing data, these Virucidal Studies show Xlear is not just antiviral, it is virucidal (kills/deactivates SARS-CoV-2).

Statement from the Chief Public Health Officer of Canada on November 29, 2020

Sunday, November 29, 2020 - 5:00pm

This is why it is important for everyone to continue with individual precautions to protect ourselves, our families and our communities.

Key Points: 
  • This is why it is important for everyone to continue with individual precautions to protect ourselves, our families and our communities.
  • Both community transmission and outbreaks are contributing to COVID-19 spread in Canada, including spread to high risk populations and settings.
  • Cases are increasing among older adults, with those aged 80 years and older currently having the highest incidence rate, nationally.
  • Right now, we have a window of opportunity to act collectively together with public health authorities to bring the infection rate down to a safer trajectory.

HVAC Equipment Market Procurement Report | Roadmap to Recovery for Businesses from the Impact of COVID-19 Pandemic | SpendEdge

Sunday, November 29, 2020 - 6:45am

The new HVAC Equipment market research report from SpendEdge indicates an incremental growth during the forecast period as the business impact of COVID-19 spreads.

Key Points: 
  • The new HVAC Equipment market research report from SpendEdge indicates an incremental growth during the forecast period as the business impact of COVID-19 spreads.
  • View the full release here: https://www.businesswire.com/news/home/20201128005043/en/
    SpendEdge has announced the release of its Global HVAC Equipment Market Procurement Intelligence Report (Graphic: Business Wire)
    As the markets recover SpendEdge expects the HVAC Equipment market size to grow by USD 23 billion during the period 2020-2024.
  • Get detailed insights on the COVID-19 pandemic crisis and recovery analysis of the HVAC Equipment market.
  • Download free report sample
    Analysis of the cost and volume drivers and supply market forecasts in various regions are offered in this HVAC Equipment research report.

Colchicine shows promise as a treatment for at-home COVID-19 patients

Sunday, November 29, 2020 - 12:49am

We aim at completing patient recruitment in this large study within the next month and hope that colchicine will reduce the risk of COVID-19 complications.

Key Points: 
  • We aim at completing patient recruitment in this large study within the next month and hope that colchicine will reduce the risk of COVID-19 complications.
  • COLCORONA is a contact-free, at-home, randomized, double-blind, placebo-controlled study run out of Canada, the United States, Europe, South America, and South Africa.
  • It aims to determine if colchicine can reduce the risk of serious complications linked to COVID-19.
  • This is one of the few current large-scale studies of COVID-19 in which non-hospitalized patients can participate.

Statement from the Chief Public Health Officer of Canada on November 28, 2020

Saturday, November 28, 2020 - 5:35pm

This is why it is important for everyone to continue with individual precautions to protect ourselves, our families and our communities.

Key Points: 
  • This is why it is important for everyone to continue with individual precautions to protect ourselves, our families and our communities.
  • Both community transmission and outbreaks are contributing to COVID-19 spread in Canada, including spread to high risk populations and settings.
  • Right now, we have a window of opportunity to act collectively together with public health authorities to bring the infection rate down to a safer trajectory.
  • What comes next for us this Fall and Winter is for every one of us to determine, through our decisions and actions.

Medical Carts Market Procurement Report | Roadmap to Recovery for Businesses from the Impact of COVID-19 Pandemic | SpendEdge

Friday, November 27, 2020 - 4:30pm

The new Medical Carts market research report from SpendEdge indicates an incremental growth during the forecast period as the business impact of COVID-19 spreads.

Key Points: 
  • The new Medical Carts market research report from SpendEdge indicates an incremental growth during the forecast period as the business impact of COVID-19 spreads.
  • View the full release here: https://www.businesswire.com/news/home/20201127005156/en/
    SpendEdge has announced the release of its Global Medical Carts Market Procurement Intelligence Report (Graphic: Business Wire)
    As the markets recover, SpendEdge expects the Medical Carts market size to grow by USD 1 billion during the period 2020-2024.
  • Get detailed insights on the COVID-19 pandemic crisis and recovery analysis of the Medical Carts market.
  • Download free report sample
    Analysis of the cost and volume drivers and supply market forecasts in various regions are offered in this Medical Carts research report.

Mybiopassport Launches The “COVID-19 & Immunity Profile” At-home Blood Collection Test

Friday, November 27, 2020 - 3:48pm

A Swiss biotechnology company with their Swissmedic authorized laboratory based in Geneva, announced today the launch of its e-Commerce platform www.mybiopassport.com , where anyone can order the COVID-19 & Immunity Profile test, and soon-to-be-released Nutritional Profile and Sports Performance Profile tests.

Key Points: 
  • A Swiss biotechnology company with their Swissmedic authorized laboratory based in Geneva, announced today the launch of its e-Commerce platform www.mybiopassport.com , where anyone can order the COVID-19 & Immunity Profile test, and soon-to-be-released Nutritional Profile and Sports Performance Profile tests.
  • The mybiopassport COVID-19 & Immunity Profile lets clients know if they were previously infected by the SARS-CoV-2 virus through the development of specific antibodies.
  • More importantly, this blood test also delivers actionable nutritional recommendations based on a set of key biomarkers of the immune system.
  • The COVID-19 & Immunity test can be ordered at www.mybiopassport.com and personalized results are delivered to each individual on the online portal.

DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies

Friday, November 27, 2020 - 1:00pm

STI-2020-encoded Gene MAb is in development for intramuscular injection against the SARS-CoV-2 virus and its variant strains to produce potent STI-2020 nAbs in the body.

Key Points: 
  • STI-2020-encoded Gene MAb is in development for intramuscular injection against the SARS-CoV-2 virus and its variant strains to produce potent STI-2020 nAbs in the body.
  • For this Gene MAb approach, the SmartPharm/Sorrento team will produce plasmid DNA encoding the SARS-CoV-2 neutralizing antibody STI-2020 (COVI-AMG).
  • The FDA is currently reviewing IND filings for STI-2020 as an IV-delivered neutralizing antibody and STI-2099 as an intranasal-delivered neutralizing antibody for the treatment of COVID-19.
  • The expected higher potency of the STI-2020 antibody makes it an ideal candidate for Gene MAb delivery against COVID-19.

Veritas offers a genomic analysis to determine an individual's response to COVID-19

Friday, November 27, 2020 - 8:53am

The analysis looks at three groups of genomic variants, the first one identifies those related to the drugs used to treat COVID-19.

Key Points: 
  • The analysis looks at three groups of genomic variants, the first one identifies those related to the drugs used to treat COVID-19.
  • The final group studies the genetic factors related to cardiopulmonary complications in the event of an infection with SARS-CoV-2.
  • A saliva sample is used to perform the analysis so anyone can easily access the service through Veritas or Veritas partners network.
  • Since its inception, Veritas Intercontinental has led the activity and development of Veritas in Europe, Latin America, the MiddleEastand Japan.

Veritas offers a genomic analysis to determine an individual's response to COVID-19

Friday, November 27, 2020 - 8:51am

The analysis looks at three groups of genomic variants, the first one identifies those related to the drugs used to treat COVID-19.

Key Points: 
  • The analysis looks at three groups of genomic variants, the first one identifies those related to the drugs used to treat COVID-19.
  • The final group studies the genetic factors related to cardiopulmonary complications in the event of an infection with SARS-CoV-2.
  • A saliva sample is used to perform the analysis so anyone can easily access the service through Veritas or Veritas partners network.
  • Since its inception, Veritas Intercontinental has led the activity and development of Veritas in Europe, Latin America, the MiddleEastand Japan.